

# STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2001 GEORGIA

## LIST OF TABLES

### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

### FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

### FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

**FOR DUAL ELIGIBLE BENEFICIARIES**

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

**SUPPLEMENTAL TABLES**

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

**APPENDIX TABLE**

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY<sup>a,b</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	No. of Benefes						No. of Bene Mos						Other/ Unknown
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown	
<b>All</b>	<b>1,212,916</b>	<b>4,792</b>	<b>135,436</b>	<b>262,261</b>	<b>810,036</b>	<b>391</b>	<b>9,894,227</b>	<b>45,717</b>	<b>1,436,739</b>	<b>1,901,970</b>	<b>6,508,241</b>	<b>1,560</b>	
<b>Age</b>													
5 and younger	395,681	2	8,833	77	386,769	0	3,099,662	18	90,611	620	3,008,413	0	
6-14	339,231	1	20,641	290	318,299	0	2,920,795	9	229,428	1,931	2,689,427	0	
15-20	152,949	0	13,295	38,899	100,735	20	1,233,203	0	145,730	294,928	792,442	103	
21-44	257,662	0	41,612	211,772	4,112	166	1,990,306	0	441,621	1,530,718	17,265	702	
45-64	59,959	384	48,261	11,103	6	205	575,152	3,290	497,859	73,216	32	755	
65-74	4,313	1,852	2,400	61	0	0	45,654	18,174	27,238	242	0	0	
75-84	2,023	1,655	350	16	2	0	20,339	16,387	3,884	55	13	0	
85 and older	1,080	897	44	42	97	0	9,064	7,838	368	259	599	0	
Unknown	18	1	0	1	16	0	52	1	0	1	50	0	
<b>Gender</b>													
Female	723,466	3,076	71,314	248,143	400,542	391	5,858,946	29,437	767,900	1,824,565	3,235,484	1,560	
Male	489,448	1,716	64,122	14,118	409,492	0	4,035,273	16,280	668,839	77,405	3,272,749	0	
Unknown	2	0	0	0	2	8	0	0	0	0	8	0	
<b>Race</b>													
White	464,120	1,752	45,616	110,385	306,126	241	3,602,868	15,638	476,765	752,711	2,356,770	984	
African American	649,767	1,231	61,367	145,471	441,564	134	5,575,079	11,162	663,072	1,106,744	3,793,566	535	
Other/unknown	99,029	1,809	28,453	6,405	62,346	16	716,280	18,917	296,902	42,515	357,905	41	
<b>Use of Nursing Facilities<sup>c</sup></b>													
Entire year	2,211	730	1,478	3	0	0	23,017	7,152	15,852	13	0	0	
Part year	1,199	353	839	5	2	0	11,799	3,068	8,679	35	17	0	
None	1,209,506	3,709	133,119	262,253	810,034	391	9,859,411	35,497	1,412,208	1,901,922	6,508,224	1,560	
<b>Maintenance Assistance Status</b>													
Cash	455,893	2,397	120,579	113,400	219,517	0	4,050,760	26,030	1,317,586	803,899	1,903,245	0	
Medically needy	2,316	452	1,849	0	15	0	13,156	3,513	9,615	0	28	0	
Poverty-related	519,853	43	44	73,934	445,441	391	3,899,473	399	342	515,062	3,382,110	1,560	
Other/unknown	234,854	1,900	12,964	74,927	145,063	0	1,930,838	15,775	109,196	583,009	1,222,858	0	
<b>Managed Care Status</b>													
FFS all year	1,212,916	4,792	135,436	262,261	810,036	391	9,894,227	45,717	1,436,739	1,901,970	6,508,241	1,560	
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	No. of Benes
All	61.7 %	6.7	\$303	\$45	\$2,099	14.4 %	1,212,916
<b>Age</b>							
5 and younger	64.7	4.5	131	29	1,661	7.9	395,681
6-14	51.8	3.6	177	49	966	18.4	339,231
15-20	57.2	4.3	191	44	1,749	10.9	152,949
21-44	66.9	8.4	413	49	2,907	14.2	257,662
45-64	83.3	35.1	1,813	52	7,997	22.7	59,959
65-74	84.8	34.5	1,522	44	8,373	18.2	4,313
75-84	81.0	30.7	1,333	43	8,995	14.8	2,023
85 and older	71.0	25.5	1,031	41	9,728	10.6	1,080
Unknown	0.0	0.0	0	0	0	0.0	18
<b>Basis of Eligibility<sup>c</sup></b>							
Aged	80.4	29.1	1,282	44	8,942	14.3	4,792
Disabled	80.5	25.7	1,566	61	7,754	20.2	135,436
Adults	66.8	6.0	193	32	2,056	9.4	262,261
Children	56.7	3.7	121	33	1,124	10.8	810,036
Unknown	72.1	6.8	343	50	6,295	5.4	391
<b>Gender</b>							
Female	63.8	7.4	307	42	2,145	14.3	723,466
Male	58.4	5.8	296	51	2,030	14.6	489,448
Unknown	0.0	0.0	0	0	0	0.0	2
<b>Race</b>							
White	67.0	8.2	369	45	2,347	15.7	464,120
African American	58.9	5.4	231	42	1,735	13.3	649,767
Other/unknown	54.4	8.6	465	54	3,322	14.0	99,029
<b>Use of Nursing Facilities<sup>d</sup></b>							
Entire year	98.6	59.6	3,103	52	38,395	8.1	2,211
Part year	97.4	52.9	2,906	55	33,828	8.6	1,199
None	61.6	6.6	295	45	2,001	14.7	1,209,506
<b>Maintenance Assistance Status</b>							
Cash	63.9	10.7	557	52	2,988	18.6	455,893
Medically needy	81.8	22.8	1,340	59	9,492	14.1	2,316
Poverty related	57.6	3.6	111	31	1,211	9.2	519,853
Other/unknown	66.1	5.7	223	39	2,264	9.8	234,854

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
  - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:						Mean \$, All Services	Benes	Bene Mos
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	Less than 5, but 10 or More	More than 10			
All	0.8	\$37	14.4 %	38.3 %	48.1 %	6.6 %	5.1 %	1.5 %	0.3 %	\$257	1,212,916	9,894,227
<b>Age</b>												
5 and younger	0.6	17	7.9	35.3	55.6	6.6	2.4	0.1	0.0	212	395,681	3,099,662
6-14	0.4	21	18.4	48.2	45.4	4.0	2.2	0.2	0.0	112	339,231	2,920,795
15-20	0.5	24	10.9	42.8	48.6	5.5	2.8	0.3	0.0	217	152,949	1,233,203
21-44	1.1	54	14.2	33.1	47.1	9.3	8.2	2.1	0.3	376	257,662	1,990,306
45-64	3.7	189	22.7	16.7	20.3	12.4	29.2	17.6	3.9	834	59,959	575,152
65-74	3.3	144	18.2	15.2	21.1	13.7	31.9	15.3	2.8	791	4,313	45,654
75-84	3.1	133	14.8	19.0	20.8	12.9	29.7	15.2	2.4	895	2,023	20,339
85 and older	3.0	123	10.6	29.0	18.8	10.9	23.4	15.6	2.2	1,159	1,080	9,064
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0	18	52
<b>Basis of Eligibility<sup>c</sup></b>												
Aged	3.1	134	14.3	19.6	21.3	13.1	29.2	14.2	2.7	937	4,792	45,717
Disabled	2.4	148	20.2	19.5	33.2	12.5	22.0	10.7	2.2	731	135,436	1,436,739
Adults	0.8	27	9.4	33.2	51.4	8.6	5.7	1.0	0.1	284	262,261	1,901,970
Children	0.5	15	10.8	43.3	49.7	5.0	1.9	0.1	0.0	140	810,036	6,508,241
Unknown	1.7	86	5.4	27.9	33.2	15.9	17.9	4.6	0.5	1,578	391	1,560
<b>Gender</b>												
Female	0.9	38	14.3	36.2	49.2	6.9	5.5	1.9	0.4	265	723,466	5,858,946
Male	0.7	36	14.6	41.6	46.4	6.3	4.5	1.1	0.1	246	489,448	4,035,273
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0	2	8
<b>Race</b>												
White	1.1	48	15.7	33.0	49.5	8.5	6.6	2.1	0.4	302	464,120	3,602,868
African American	0.6	27	13.3	41.1	48.8	5.3	3.7	1.0	0.1	202	649,767	5,575,079
Other/unknown	1.2	64	14.0	45.6	36.8	7.0	7.3	2.8	0.5	459	99,029	716,280
<b>Use of Nursing Facilities<sup>d</sup></b>												
Entire year	5.7	298	8.1	1.4	7.3	10.4	34.2	35.8	10.8	3,688	2,211	23,017
Part year	5.4	295	8.6	2.6	10.6	11.5	34.0	32.0	9.3	3,438	1,199	11,799
None	0.8	36	14.7	38.4	48.2	6.6	5.0	1.4	0.2	246	1,209,506	9,859,411
<b>Maintenance Assistance Status</b>												
Cash	1.2	63	18.6	36.1	43.3	7.6	8.9	3.4	0.6	336	455,893	4,050,760
Medically needy	4.0	236	14.1	18.2	13.9	11.4	31.2	20.8	4.4	1,671	2,316	13,156
Poverty related	0.5	15	9.2	42.4	49.9	5.5	2.1	0.1	0.0	161	519,853	3,899,473
Other/unknown	0.7	27	9.8	33.9	53.7	7.2	4.3	0.8	0.1	275	234,854	1,930,838

Table ND4

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.5

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	No. of Rx	Rx \$	\$ per Rx	No. of Rx	Rx \$	\$ per Rx	No. of Rx	Rx \$	\$ per Rx	No. of Rx	Rx \$	\$ per Rx
All	0.8	\$37	\$45	0.4	\$29	\$75	0.1	\$2	\$37	0.4	\$6	\$16
<b>Age</b>												
5 and younger	0.6	17	29	0.2	12	51	0.1	1	19	0.3	3	12
6-14	0.4	21	49	0.2	16	73	0.0	1	34	0.2	4	21
15-20	0.5	24	44	0.2	18	74	0.0	2	40	0.3	4	16
21-44	1.1	54	49	0.5	42	88	0.1	4	53	0.5	8	15
45-64	3.7	189	52	1.7	147	84	0.2	11	48	1.7	31	19
65-74	3.3	144	44	1.6	110	69	0.2	8	40	1.4	26	18
75-84	3.1	133	43	1.4	99	69	0.2	9	38	1.4	24	18
85 and older	3.0	123	41	1.3	86	66	0.3	10	37	1.4	27	18
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
<b>Basis of Eligibility<sup>d</sup></b>												
Aged	3.1	134	44	1.5	102	68	0.2	8	39	1.3	24	18
Disabled	2.4	148	61	1.2	115	99	0.2	10	56	1.1	23	21
Adults	0.8	27	32	0.3	20	58	0.0	2	34	0.4	5	12
Children	0.5	15	33	0.2	11	54	0.0	1	21	0.2	3	13
Unknown	1.7	86	50	0.7	70	107	0.1	3	39	1.0	13	13
<b>Gender</b>												
Female	0.9	38	42	0.4	29	70	0.1	3	37	0.4	6	15
Male	0.7	36	51	0.3	28	84	0.1	2	37	0.3	6	19
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
<b>Race</b>												
White	1.1	48	45	0.5	36	75	0.1	3	39	0.5	8	16
African American	0.6	27	42	0.3	21	72	0.0	2	32	0.3	5	15
Other/unknown	1.2	64	54	0.6	50	88	0.1	4	42	0.5	11	20
<b>Use of Nursing Facilities<sup>e</sup></b>												
Entire year	5.7	298	52	2.3	214	92	0.6	28	46	2.8	56	20
Part year	5.4	295	55	2.3	222	95	0.5	23	48	2.5	51	20
None	0.8	36	45	0.4	28	75	0.1	2	36	0.4	6	16
<b>Maintenance Assistance</b>												
<b>Status</b>												
Cash	1.2	63	52	0.6	49	87	0.1	4	46	0.6	10	18
Medically needy	4.0	236	59	2.0	181	92	0.2	12	50	1.8	43	24
Poverty related	0.5	15	31	0.2	11	51	0.0	1	22	0.2	3	12
Other/unknown	0.7	27	39	0.3	21	65	0.1	2	31	0.3	5	15

Table ND5

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented	Off-Patent	Total	Patented	Off-Patent	Total	Patented	Off-Patent	Generic	Total No. of Rx	Total Rx \$	No.	As % of All Benes	No. of Bene Mos		
																Brand-Name	Brand-Name
Anti-infective Agents	0.3	0.2	0.0	0.1	\$11	\$10	\$0	\$1	\$43	\$66	\$35	\$10	1,341,893	\$57,163,336	515,330	42.5%	4,972,407
Biologicals	0.5	0.4	0.0	0.0	598	478	37	83	1290	1,162	2,389	2,268	6,580	8,486,686	1,653	0.1	14,197
Antineoplastic Agents	0.4	0.2	0.1	0.2	95	72	13	11	214	364	169	63	16,529	3,530,258	3,679	0.3	37,110
Endocrine/Metabolic Drugs	0.4	0.2	0.0	0.1	14	11	1	1	37	51	24	13	644,598	23,721,494	174,602	14.4	1,702,368
Cardiovascular Agents	1.1	0.5	0.1	0.6	36	25	2	10	33	53	30	17	834,213	27,768,748	74,642	6.2	763,074
Respiratory Agents	0.4	0.2	0.1	0.1	13	9	1	3	34	56	18	18	1,518,755	52,213,155	422,309	34.8	4,109,738
Gastrointestinal Agents	0.4	0.2	0.0	0.2	25	21	2	3	66	103	104	16	348,797	22,938,304	91,204	7.5	906,066
Genitourinary Agents	0.2	0.2	0.0	0.0	7	6	0	0	33	39	26	10	133,977	4,461,201	69,342	5.7	655,815
CNS Drugs	0.6	0.3	0.0	0.3	49	39	5	6	78	123	112	20	809,301	63,113,704	125,127	10.3	1,277,641
Stimulants/Anti-obesity/Anorexia	0.5	0.3	0.0	0.2	29	21	1	7	53	67	46	32	196,303	10,330,310	34,602	2.9	362,082
Miscellaneous Psychological/Neurological Agents	0.5	0.3	0.0	0.2	48	43	0	5	98	168	27	22	8,677	846,835	1,654	0.1	17,715
Analgesics and Anesthetics	0.4	0.1	0.0	0.3	12	8	1	3	32	95	49	11	940,954	30,367,045	252,528	20.8	2,473,563
Neuromuscular Agents	0.6	0.3	0.1	0.3	34	26	2	6	57	101	39	20	423,819	24,001,305	67,752	5.6	704,661
Nutritional Products	0.3	0.1	0.1	0.2	4	1	1	2	14	17	20	12	209,704	2,967,981	80,700	6.7	713,808
Hematological Agents	0.5	0.2	0.1	0.2	105	76	5	24	217	470	52	106	66,453	14,431,073	13,566	1.1	137,621
Topical Products	0.2	0.1	0.0	0.1	6	4	0	2	27	43	35	14	640,952	17,264,230	289,896	23.9	2,855,668
Miscellaneous Products	0.2	0.1	0.0	0.0	27	23	2	2	139	161	262	52	21,316	2,955,760	10,700	0.9	108,705
Unknown Therapeutic Category	0.1	0.0	0.0	0.0	3	0	0	0	21	0	0	0	16,813	352,311	11,162	0.9	116,982
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	8,179,634	366,913,736	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2001. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Top 10 Drug Groups	Users				Among Users		
	Total Medicaid Rx \$	No. As % of All Benes	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo	
ANTIPSYCHOTICS	\$34,719,584	38,456	421,221	0.5	\$158	\$82	
ANTIASTHMATIC	25,864,379	212,174	2,140,838	0.3	47	12	
ANTIDEPRESSANTS	23,682,011	91,399	939,971	0.4	62	25	
ANTICONVULSANT	19,893,623	41,468	447,338	0.6	76	44	
ULCER DRUGS	19,378,871	88,955	899,662	0.3	73	22	
ANTIVIRAL	15,608,738	19,144	194,600	0.3	271	80	
ANALGESICS - Narcotic	15,460,193	235,607	2,340,374	0.2	28	7	
ANTIDIABETIC	12,071,184	35,034	368,383	0.6	54	33	
ANALGESICS - ANTI-INFLAMMATORY	12,042,952	164,788	1,666,335	0.2	37	7	
DERMATOLOGICAL	11,479,503	268,478	2,721,479	0.1	28	4	
Total	190,201,038	1,195,503	12,140,201	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED  
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE<sup>a,b,c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	All Top 10 Drug Groups					ANTI-PSYCHOTICS					ANTI-ASTHMATIC				
	No. of Rx	Rx \$	No. of Users	Users as % of All Benes	Mean No. of Rx	No. of Users	Users as % of All Benes	Mean No. of Rx	No. of Users	Users as % of All Benes	Mean No. of Rx	No. of Users	Users as % of All Benes	Mean No. of Rx	Rx \$
<b>All</b>	<b>3,246,902</b>	<b>\$190,201,038</b>	<b>38,456</b>	<b>3.2 %</b>	<b>0.5</b>	<b>421,221</b>	<b>3.2 %</b>	<b>\$82</b>	<b>212,174</b>	<b>17.5 %</b>	<b>2,140,838</b>	<b>17.5 %</b>	<b>0.3</b>	<b>\$12</b>	
<b>Female</b>	2,134,226	118,624,307	21,689	3.0	0.5	235,919	3.0	77	111,821	15.5	1,131,117	15.5	0.3	12	
<b>Disabled</b>	1,103,421	78,916,361	15,204	21.3	0.6	173,096	21.3	90	27,969	39.2	316,472	39.2	0.4	21	
5 and younger	14,836	847,066	39	1.0	0.4	452	1.0	44	2,025	53.3	22,885	53.3	0.3	16	
6-14	38,058	2,820,308	665	8.9	0.5	7,705	8.9	68	2,208	29.6	25,719	29.6	0.3	18	
15-20	31,012	2,343,526	774	15.1	0.5	8,915	15.1	76	1,003	19.5	11,531	19.5	0.3	14	
21-44	326,006	25,901,026	6,369	27.9	0.5	72,189	27.9	90	6,837	29.9	77,498	29.9	0.3	17	
45-64	656,113	44,856,703	7,034	23.5	0.6	80,106	23.5	94	15,090	50.3	169,614	50.3	0.4	24	
65-74	33,554	1,951,910	282	15.8	0.7	3,269	15.8	90	742	41.6	8,509	41.6	0.5	23	
75-84	3,619	183,281	39	14.9	0.7	445	14.9	61	59	22.5	656	22.5	0.3	14	
85 and older	223	12,541	2	6.5	1.0	15	6.5	218	5	16.1	60	16.1	0.2	8	
<b>Other Eligibles</b>	1,030,805	39,707,946	6,485	1.0	0.3	62,823	1.0	40	83,852	12.9	814,645	12.9	0.2	9	
5 and younger	203,321	5,753,308	93	0.0	0.3	989	0.0	35	39,887	20.9	386,366	20.9	0.2	8	
6-14	146,573	6,060,904	1,295	0.8	0.4	14,044	0.8	47	18,741	11.8	192,823	11.8	0.2	10	
15-20	123,776	4,298,760	1,068	1.2	0.3	10,799	1.2	36	7,151	8.2	70,435	8.2	0.2	9	
21-44	470,876	18,807,946	3,351	1.7	0.3	30,719	1.7	33	15,952	7.9	145,037	7.9	0.2	10	
45-64	56,833	3,139,392	364	3.8	0.4	3,159	3.8	59	1,569	16.6	14,304	16.6	0.4	18	
65-74	11,126	628,528	72	6.3	0.6	686	6.3	86	214	18.6	2,259	18.6	0.4	17	
75-84	11,732	656,520	124	11.6	0.6	1,312	11.6	76	205	19.2	2,125	19.2	0.4	20	
85 and older	6,568	362,588	118	16.3	0.6	1,115	16.3	56	133	18.3	1,296	18.3	0.4	16	
<b>Male</b>	1,112,676	71,576,731	16,767	3.4	0.6	185,302	3.4	90	100,353	20.5	1,009,721	20.5	0.2	12	
<b>Disabled</b>	590,998	49,534,985	11,997	18.7	0.6	135,664	18.7	101	17,608	27.5	196,470	27.5	0.4	20	
5 and younger	21,626	1,284,799	138	2.7	0.4	1,574	2.7	47	3,096	61.5	34,952	61.5	0.3	18	
6-14	65,016	4,872,568	2,009	15.2	0.5	23,125	15.2	72	4,256	32.3	49,422	32.3	0.3	16	
15-20	41,204	3,548,982	1,397	17.1	0.5	15,970	17.1	90	1,329	16.3	15,395	16.3	0.3	16	
21-44	188,883	19,267,661	5,323	28.4	0.7	60,250	28.4	117	2,206	11.8	24,396	11.8	0.4	18	
45-64	265,214	20,018,835	3,020	16.5	0.6	33,499	16.5	101	6,441	35.2	69,183	35.2	0.5	26	
65-74	8,016	475,582	93	15.0	0.7	1,070	15.0	74	255	41.3	2,886	41.3	0.5	25	
75-84	960	62,826	15	17.0	0.7	154	17.0	76	22	25.0	200	25.0	0.4	19	
85 and older	79	3,732	2	15.4	0.5	22	15.4	41	3	23.1	36	23.1	0.4	8	
<b>Other Eligibles</b>	521,678	22,041,746	4,770	1.1	0.4	49,638	1.1	59	82,745	19.5	813,251	19.5	0.2	10	
5 and younger	235,412	7,433,571	237	0.1	0.3	2,524	0.1	37	52,794	27.0	508,350	27.0	0.2	9	
6-14	165,510	8,195,406	3,005	1.9	0.4	32,621	1.9	58	24,191	15.2	249,128	15.2	0.2	11	
15-20	57,333	2,906,672	1,033	2.0	0.5	10,355	2.0	64	4,103	7.9	41,419	7.9	0.2	11	
21-44	34,084	1,791,894	266	1.9	0.4	2,000	1.9	54	790	5.5	5,954	5.5	0.3	15	
45-64	13,604	827,881	73	3.3	0.4	604	3.3	62	420	18.7	3,718	18.7	0.4	22	
65-74	6,837	405,017	48	6.3	0.6	516	6.3	81	227	29.8	2,417	29.8	0.3	15	
75-84	6,219	354,627	71	11.8	0.7	676	11.8	81	125	20.7	1,299	20.7	0.4	21	
85 and older	2,679	126,678	37	11.9	0.7	342	11.9	47	95	30.5	966	30.5	0.5	25	
<b>Unknown</b>	0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0.0	0	

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	ANTIDEPRESSANTS					ANTICONVULSANT					ULCER DRUGS				
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>91,399</b>	<b>7.5 %</b>	<b>939,971</b>	<b>0.4</b>	<b>\$25</b>	<b>41,468</b>	<b>3.4 %</b>	<b>447,338</b>	<b>0.6</b>	<b>\$45</b>	<b>88,955</b>	<b>7.3 %</b>	<b>899,662</b>	<b>0.3</b>	<b>\$22</b>
<b>Female</b>	67,103	9.3	684,127	0.4	25	24,377	3.4	261,003	0.6	43	61,356	8.5	626,922	0.3	22
<b>Disabled</b>	30,940	43.4	347,600	0.5	31	16,073	22.5	181,847	0.6	50	26,282	36.9	298,034	0.4	32
5 and younger	37	1.0	435	0.3	15	405	10.7	4,494	0.6	57	580	15.3	6,203	0.3	15
6-14	823	11.0	9,451	0.4	23	1,452	19.5	16,727	0.7	55	593	7.9	6,999	0.3	19
15-20	1,059	20.6	12,103	0.4	27	1,018	19.8	11,713	0.7	62	629	12.2	7,222	0.2	17
21-44	11,164	48.8	125,821	0.4	30	6,126	26.8	69,429	0.6	53	7,487	32.7	85,663	0.3	26
45-64	17,227	57.5	192,541	0.5	32	6,772	22.6	75,977	0.6	43	15,989	53.3	180,426	0.4	37
65-74	565	31.7	6,529	0.6	30	267	15.0	3,116	0.7	33	896	50.3	10,406	0.5	36
75-84	60	22.9	660	0.6	26	29	11.1	347	0.7	33	96	36.6	1,084	0.5	33
85 and older	5	16.1	60	0.5	16	4	12.9	44	0.8	40	12	38.7	131	0.4	35
<b>Other Eligibles</b>	36,163	5.5	336,527	0.3	19	8,304	1.3	79,156	0.4	27	35,074	5.4	328,888	0.2	13
5 and younger	171	0.1	1,836	0.2	8	428	0.8	4,421	0.4	24	7,741	4.0	66,382	0.2	5
6-14	3,840	2.4	40,875	0.3	18	1,295	0.2	13,778	0.5	31	3,625	2.3	38,473	0.1	7
15-20	5,136	5.9	50,165	0.3	18	1,051	1.2	10,515	0.4	30	4,138	4.7	40,807	0.2	9
21-44	23,873	11.8	215,349	0.3	19	4,743	2.4	43,084	0.4	24	16,329	8.1	152,372	0.2	16
45-64	2,518	26.6	21,806	0.4	25	551	5.8	4,928	0.4	31	2,208	23.4	19,847	0.3	29
65-74	228	19.8	2,377	0.5	24	90	7.8	934	0.7	33	437	38.0	4,702	0.4	30
75-84	242	22.6	2,561	0.6	36	94	8.8	1,006	0.7	34	390	36.5	4,207	0.5	33
85 and older	155	21.4	1,558	0.6	39	52	7.2	490	0.6	24	206	28.4	2,098	0.6	41
<b>Male</b>	24,296	5.0	255,844	0.4	25	17,091	3.5	186,335	0.6	47	27,599	5.6	272,740	0.3	20
<b>Disabled</b>	13,766	21.5	151,234	0.5	29	12,660	19.7	142,177	0.7	53	12,003	18.7	131,028	0.4	31
5 and younger	78	1.5	896	0.3	11	547	10.9	6,200	0.6	43	736	14.6	7,951	0.3	16
6-14	2,005	15.2	23,162	0.4	23	2,316	17.6	26,658	0.6	47	773	5.9	8,980	0.3	21
15-20	1,335	16.4	15,211	0.4	31	1,457	17.9	16,646	0.7	56	549	6.7	6,338	0.2	17
21-44	4,682	25.0	50,956	0.5	32	4,832	25.8	54,322	0.7	63	3,293	17.6	36,032	0.4	28
45-64	5,529	30.2	59,498	0.5	29	3,444	18.8	37,643	0.6	41	6,402	35.0	68,907	0.5	36
65-74	125	20.2	1,374	0.6	32	58	9.4	640	0.7	38	218	35.3	2,471	0.5	35
75-84	11	12.5	125	0.8	60	6	6.8	68	0.4	13	28	31.8	308	0.7	55
85 and older	1	7.7	12	0.1	5	0	0.0	0	0.0	0	4	30.8	41	0.5	42
<b>Other Eligibles</b>	10,530	2.5	104,610	0.4	20	4,431	1.0	44,158	0.5	30	15,596	3.7	141,712	0.2	10
5 and younger	275	0.1	2,959	0.2	9	628	0.3	6,451	0.4	22	8,843	4.5	75,851	0.2	5
6-14	5,681	3.6	60,471	0.4	19	2,052	1.3	21,751	0.5	28	3,110	2.0	32,874	0.2	8
15-20	2,233	4.3	22,094	0.4	23	831	1.6	8,107	0.5	36	1,361	2.6	13,599	0.2	11
21-44	1,579	11.0	12,292	0.3	20	589	4.1	4,697	0.4	34	1,260	8.8	9,758	0.3	27
45-64	476	21.2	3,868	0.4	29	193	8.6	1,664	0.5	38	444	19.8	3,640	0.4	35
65-74	123	16.1	1,307	0.5	24	70	9.2	775	0.6	26	290	38.1	3,087	0.4	31
75-84	114	18.9	1,152	0.6	36	46	7.6	496	0.6	25	217	35.9	2,242	0.5	35
85 and older	49	15.8	467	0.6	31	22	7.1	217	0.7	28	71	22.8	661	0.5	34
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7B  
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.7C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	ANTIVIRAL				ANALGESICS - Narcotic				ANTIDIABETIC						
	No. of Users	Users as % of All Benes	No. of Bene among Mos	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene among Mos	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene among Mos	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>19,144</b>	<b>1.6 %</b>	<b>194,600</b>	<b>0.3</b>	<b>\$80</b>	<b>235,607</b>	<b>19.4 %</b>	<b>2,340,374</b>	<b>0.2</b>	<b>\$7</b>	<b>35,034</b>	<b>2.9 %</b>	<b>368,383</b>	<b>0.6</b>	<b>\$33</b>
<b>Female</b>	12,728	1.8	128,571	0.3	66	183,840	25.4	1,811,966	0.2	6	26,896	3.7	284,527	0.6	33
<b>Disabled</b>	4,412	6.2	49,181	0.4	115	49,898	70.0	565,397	0.3	12	18,491	25.9	208,291	0.6	35
5 and younger	75	2.0	870	0.3	33	308	8.1	3,528	0.1	1	8	0.2	94	1.1	94
6-14	254	3.4	2,980	0.5	109	923	12.4	10,872	0.1	3	67	0.9	789	0.8	43
15-20	107	2.1	1,189	0.2	36	1,607	31.3	18,446	0.2	4	147	2.9	1,627	0.6	33
21-44	2,406	10.5	26,500	0.4	123	18,417	80.5	209,646	0.3	11	3,393	14.8	38,613	0.6	32
45-64	1,512	5.0	16,964	0.3	114	27,340	91.2	307,705	0.4	14	13,947	46.5	156,353	0.6	36
65-74	53	3.0	618	0.3	73	1,151	64.6	13,454	0.3	10	841	47.2	9,791	0.7	33
75-84	5	1.9	60	0.1	6	139	53.1	1,614	0.3	8	86	32.8	1,002	0.7	27
85 and older	0	0.0	0	0.0	0	13	41.9	132	0.3	3	2	6.5	22	0.3	6
<b>Other Eligibles</b>	8,316	1.3	79,390	0.2	36	133,942	20.5	1,246,569	0.2	3	8,405	1.3	76,236	0.5	26
5 and younger	971	0.5	9,966	0.2	12	4,568	2.4	47,619	0.1	1	56	0.0	558	0.6	29
6-14	955	0.6	10,210	0.2	30	8,561	5.4	89,581	0.1	1	350	0.2	3,528	0.7	36
15-20	1,343	1.5	13,032	0.2	18	23,364	26.6	223,010	0.1	1	584	0.7	5,581	0.6	32
21-44	4,796	2.4	43,875	0.2	46	91,582	45.4	833,238	0.2	3	5,074	2.5	44,927	0.5	23
45-64	207	2.2	1,812	0.2	77	4,842	51.2	42,207	0.3	9	1,586	16.8	13,586	0.6	30
65-74	19	1.7	201	0.2	24	420	36.5	4,566	0.2	7	341	29.6	3,600	0.6	28
75-84	17	1.6	204	0.1	8	404	37.8	4,415	0.3	8	281	26.3	3,089	0.7	26
85 and older	8	1.1	90	0.1	11	201	27.7	1,933	0.4	12	133	18.3	1,367	0.7	22
<b>Male</b>	6,416	1.3	66,029	0.4	108	51,767	10.6	528,408	0.2	9	8,138	1.7	83,856	0.6	34
<b>Disabled</b>	4,099	6.4	42,670	0.5	153	23,814	37.1	258,967	0.3	16	6,392	10.0	68,344	0.6	34
5 and younger	119	2.4	1,380	0.3	56	524	10.4	5,959	0.1	1	9	0.2	101	0.7	27
6-14	203	1.5	2,354	0.4	72	1,429	10.8	16,696	0.1	2	65	0.5	727	0.8	41
15-20	112	1.4	1,266	0.2	36	1,589	19.5	18,218	0.2	5	84	1.0	954	0.5	30
21-44	2,134	11.4	21,226	0.5	155	7,979	42.6	86,833	0.3	15	1,327	7.1	14,355	0.6	32
45-64	1,524	8.3	16,390	0.5	178	11,935	65.3	127,230	0.4	21	4,738	25.9	50,350	0.6	35
65-74	7	1.1	54	0.4	269	314	50.8	3,538	0.3	13	148	23.9	1,651	0.7	34
75-84	0	0.0	0	0.0	0	40	45.5	445	0.3	6	21	23.9	206	0.7	32
85 and older	0	0.0	0	0.0	0	4	30.8	48	0.5	8	0	0.0	0	0.0	0
<b>Other Eligibles</b>	2,317	0.5	23,359	0.2	26	27,953	6.6	269,441	0.2	3	1,746	0.4	15,512	0.6	30
5 and younger	986	0.5	9,990	0.1	9	6,370	3.3	65,969	0.1	1	50	0.0	457	0.5	24
6-14	765	0.5	8,023	0.2	28	8,705	5.5	91,543	0.1	1	284	0.2	2,715	0.7	39
15-20	359	0.7	3,524	0.2	25	5,940	11.4	57,884	0.1	1	207	0.4	2,004	0.6	34
21-44	139	1.0	1,178	0.3	101	5,211	36.3	38,611	0.4	13	434	3.0	3,204	0.5	27
45-64	43	1.9	376	0.4	160	1,173	52.3	9,581	0.4	17	378	16.9	2,981	0.6	29
65-74	13	1.7	141	0.3	144	264	34.6	2,833	0.3	5	174	22.8	1,838	0.6	27
75-84	10	1.7	106	0.2	19	212	35.1	2,282	0.3	7	162	26.8	1,744	0.7	27
85 and older	2	0.6	21	0.1	9	78	25.1	738	0.3	8	57	18.3	569	0.7	23
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C  
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY, BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	ANALGESICS - ANTI-INFLAMMATORY				DERMATOLOGICAL							
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Benes	No. of Bene Mos
<b>All</b>	<b>164,788</b>	<b>13.6 %</b>	<b>1,666,335</b>	<b>0.2</b>	<b>\$7</b>	<b>268,478</b>	<b>22.1 %</b>	<b>2,721,479</b>	<b>0.1</b>	<b>\$4</b>	<b>1,212,916</b>	<b>9,894,227</b>
<b>Female</b>	122,540	16.9	1,227,359	0.2	8	159,315	22.0	1,614,138	0.2	4	723,458	5,858,926
<b>Disabled</b>	30,502	42.8	349,321	0.3	18	23,584	33.1	272,763	0.2	6	71,314	767,900
5 and younger	227	6.0	2,631	0.1	2	1,621	42.7	18,540	0.1	3	3,796	38,671
6-14	731	9.8	8,587	0.2	5	2,530	33.9	29,562	0.1	5	7,465	83,042
15-20	1,124	21.9	13,074	0.2	7	1,641	31.9	19,168	0.1	5	5,139	56,602
21-44	10,124	44.3	116,172	0.2	11	7,136	31.2	82,745	0.2	6	22,868	247,933
45-64	17,209	57.4	196,097	0.3	23	10,103	33.7	116,279	0.2	7	29,971	318,034
65-74	958	53.8	11,264	0.4	23	488	27.4	5,705	0.2	6	1,782	20,393
75-84	122	46.6	1,421	0.4	26	61	23.3	718	0.2	7	262	2,962
85 and older	7	22.6	75	0.3	11	4	12.9	46	0.2	6	31	263
<b>Other Eligibles</b>	92,038	14.1	878,038	0.2	4	135,731	20.8	1,341,375	0.1	4	652,144	5,091,026
5 and younger	9,688	5.1	99,502	0.1	1	65,896	34.5	640,470	0.1	3	191,171	1,487,967
6-14	10,139	6.4	107,827	0.1	1	30,689	19.3	324,347	0.1	4	159,153	1,345,984
15-20	17,137	19.5	166,115	0.1	2	13,545	15.4	136,188	0.1	5	87,729	690,767
21-44	50,568	25.1	462,921	0.2	4	23,263	11.5	217,328	0.2	5	201,691	1,474,756
45-64	3,437	36.4	29,926	0.3	15	1,488	15.7	13,746	0.2	7	9,455	63,679
65-74	539	46.8	5,897	0.4	24	319	27.7	3,501	0.2	7	1,151	11,230
75-84	380	35.5	4,298	0.4	26	294	27.5	3,300	0.2	7	1,069	10,581
85 and older	150	20.7	1,552	0.4	28	237	32.7	2,495	0.2	9	725	6,062
<b>Male</b>	42,248	8.6	438,976	0.2	6	109,163	22.3	1,107,341	0.1	4	489,440	4,035,249
<b>Disabled</b>	13,558	21.1	151,119	0.3	13	15,245	23.8	174,215	0.2	6	64,122	668,839
5 and younger	310	6.2	3,619	0.1	2	1,920	38.1	21,803	0.1	4	5,037	51,940
6-14	969	7.4	11,375	0.1	5	3,470	26.3	40,781	0.1	4	13,176	146,386
15-20	1,171	14.4	13,484	0.1	3	1,901	23.3	22,225	0.2	6	8,156	89,128
21-44	4,277	22.8	47,437	0.2	9	3,877	20.7	43,781	0.2	7	18,744	193,688
45-64	6,572	35.9	72,228	0.3	19	3,916	21.4	43,832	0.2	9	18,290	179,825
65-74	222	35.9	2,571	0.3	17	146	23.6	1,638	0.2	7	618	6,845
75-84	34	38.6	369	0.4	22	12	13.6	119	0.3	40	88	922
85 and older	3	23.1	36	0.1	4	3	23.1	36	0.2	5	13	105
<b>Other Eligibles</b>	28,690	6.7	287,857	0.1	3	93,918	22.1	933,126	0.1	4	425,318	3,366,410
5 and younger	10,755	5.5	110,021	0.1	1	62,214	31.8	602,210	0.1	3	195,677	1,521,084
6-14	8,567	5.4	91,414	0.1	2	23,557	14.8	249,781	0.1	4	159,437	1,345,383
15-20	5,616	10.8	56,124	0.1	2	6,586	12.7	67,168	0.2	8	51,925	396,706
21-44	2,558	17.8	19,125	0.2	10	765	5.3	5,958	0.2	7	14,359	73,929
45-64	636	28.4	5,065	0.3	17	253	11.3	2,149	0.2	7	2,243	13,614
65-74	304	39.9	3,329	0.3	21	241	31.6	2,673	0.2	10	762	7,186
75-84	193	32.0	2,130	0.4	28	188	31.1	2,048	0.2	8	604	5,874
85 and older	61	19.6	649	0.4	25	114	36.7	1,139	0.2	7	311	2,634
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	18	52

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8  
**MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001**

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
<b>All</b>	<b>\$298</b>	<b>5.7</b>	<b>2,211</b>	<b>23,017</b>
<b>Age</b>				
0-64	330	6.0	1,386	14,737
65-74	278	5.7	255	2,706
75-84	244	5.5	293	2,925
85 and older	202	4.7	277	2,649
Unknown	0	0.0	0	0
<b>Gender</b>				
Female	307	5.9	1,312	13,786
Male	285	5.4	899	9,231
Unknown	0	0.0	0	0
<b>Race</b>				
White	311	6	1,061	10,808
African American	281	5.4	939	9,990
Other/unknown	311	6.1	211	2,219
<b>Basis of Eligibility<sup>c</sup></b>				
Aged	246	5.4	730	7,152
Disabled	322	5.9	1,478	15,852
Adults	211	3.7	3	13
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2001 Medicaid enrollment. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented Brand-Name	Off-Patent Brand-Name	Total	Patented Brand-Name	Off-Patent Brand-Name	Total	Patented Brand-Name	Off-Patent Brand-Name	Total # of Rx	Total Rx \$	No.	As % of All-Year NF Residents	No. of Bene Mos			
		Generic	Generic		Generic	Generic		Generic	Generic								
Anti-infective Agents	0.4	0.2	0.0	0.2	\$27	\$23	\$0	\$3	\$69	\$108	\$62	\$19	5,864	\$405,913	1,424	64.4 %	15,206
Biologicals	0.1	0.1	0.0	0.0	4	4	0	0	35	35	0	0	3	105	3	0.1	29
Antineoplastic Agents	0.5	0.1	0.2	0.2	98	44	35	19	184	390	153	101	842	154,670	154	7.0	1,575
Endocrine/Metabolic Drugs	1.0	0.6	0.1	0.3	41	35	2	4	39	57	17	12	9,437	369,365	849	38.4	8,994
Cardiovascular Agents	1.8	0.6	0.1	1.1	56	31	4	21	30	52	33	18	26,438	802,258	1,392	63.0	14,413
Respiratory Agents	0.7	0.2	0.0	0.4	21	11	0	10	32	54	20	22	6,890	218,745	979	44.3	10,582
Gastrointestinal Agents	0.9	0.4	0.1	0.5	53	40	4	9	56	104	65	18	10,743	604,313	1,096	49.6	11,357
Genitourinary Agents	0.6	0.4	0.0	0.2	30	26	0	3	50	65	34	18	2,160	108,792	338	15.3	3,665
CNS Drugs	1.5	0.8	0.1	0.6	126	100	12	15	83	132	101	23	26,239	2,184,045	1,627	73.6	17,266
Stimulants/Anti-obesity/Anorexia	0.6	0.0	0.0	0.6	20	7	1	13	33	181	33	23	148	4,881	22	1.0	239
Miscellaneous Psychological/Neurological Agents	0.7	0.7	0.0	0.0	90	89	0	1	121	123	0	34	1,040	126,318	143	6.5	1,408
Analgesics and Anesthetics	0.9	0.4	0.0	0.5	38	30	2	7	41	83	39	13	10,396	431,282	1,093	49.4	11,379
Neuromuscular Agents	1.3	0.4	0.3	0.6	68	42	11	16	53	99	38	27	15,617	830,664	1,123	50.8	12,217
Nutritional Products	0.7	0.0	0.2	0.5	14	1	6	8	19	24	28	16	4,366	84,948	573	25.9	5,987
Hematological Agents	0.9	0.3	0.3	0.3	57	46	6	6	65	161	17	21	4,251	276,143	484	21.9	4,848
Topical Products	0.5	0.2	0.1	0.2	17	10	3	4	33	48	41	16	6,901	229,902	1,270	57.4	13,835
Miscellaneous Products	0.4	0.1	0.0	0.3	29	13	2	13	71	129	95	48	326	23,272	78	3.5	810
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	5	0	0	0	23	0	0	0	184	4,267	70	3.2	801
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	131,845	6,859,883	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2001. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003). In Georgia, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Top 10 Drug Groups in Nursing Facilities	Users				Among Users		
	Total Medicaid Rx \$	No. of Users	As % of All-Year NF Residents	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$1,291,712	1,113	50.3 %	12,129	0.7	\$147	\$106
ANTIDEPRESSANTS	699,711	1,179	53.3	12,705	0.8	69	55
ANTICONVULSANT	685,859	1,105	50.0	12,409	0.9	58	55
ULCER DRUGS	555,025	1,067	48.3	11,429	0.7	68	49
ANTIDIABETIC	308,234	791	35.8	8,614	0.9	41	36
ANTIHYPERTENSIVE	266,131	847	38.3	9,066	0.8	36	29
ANALGESICS - Narcotic	214,307	1,084	49.0	11,473	0.6	33	19
CALCIUM BLOCKERS	207,372	432	19.5	4,589	0.9	49	45
ANALGESICS - ANTI-INFLAMMATORY	194,693	547	24.7	5,995	0.5	59	32
DERMATOLOGICAL	157,303	1,640	74.2	18,338	0.2	35	9
Total	4,580,347	9,805		106,747	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	All Top 10 Drug Groups					ANTIPSYCHOTICS					ANTIDEPRESSANTS						
	No. of Rx	Rx \$	No. of Users	Users as % of All-Year Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All-Year Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All-Year Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>72,235</b>	<b>\$4,580,347</b>	<b>1,113</b>	<b>50.3 %</b>	<b>12,129</b>	<b>0.7</b>	<b>\$107</b>	<b>1,179</b>	<b>53.3 %</b>	<b>12,705</b>	<b>0.8</b>	<b>\$55</b>					
<b>Female</b>	44,458	2,870,248	685	52.2	7,508	0.7	111	760	57.9	8,268	0.8	56					
<b>Disabled</b>	31,490	2,114,774	492	60.4	5,539	0.7	117	521	64.0	5,832	0.8	58					
64 or younger	26,813	1,830,355	422	61.1	4,722	0.7	119	463	67.0	5,176	0.8	59					
65-74	3,857	243,639	62	66.7	730	0.7	110	51	54.8	572	0.8	57					
75-84	754	36,397	7	28.0	84	1.2	83	5	20.0	60	1.0	33					
85 and older	66	4,383	1	20.0	3	1.0	104	2	40.0	24	0.5	22					
<b>Other Eligibles</b>	12,968	755,474	193	38.8	1,969	0.7	94	239	48.0	2,436	0.8	49					
64 or younger	1,679	109,371	24	57.1	240	0.8	127	27	64.3	266	0.8	57					
65-74	2,590	157,276	44	55.0	460	0.7	108	46	57.5	462	0.8	42					
75-84	4,565	263,212	64	36.0	694	0.8	99	85	47.8	879	0.8	54					
85 and older	4,134	225,615	61	30.8	575	0.6	62	81	40.9	829	0.7	44					
<b>Male</b>	27,777	1,710,099	428	47.6	4,621	0.7	99	419	46.6	4,437	0.8	54					
<b>Disabled</b>	21,828	1,391,604	318	47.9	3,548	0.7	105	310	46.7	3,367	0.8	59					
64 or younger	20,626	1,308,702	299	48.1	3,335	0.7	105	286	46.1	3,098	0.8	59					
65-74	1,016	70,581	17	48.6	197	0.8	109	22	62.9	245	0.7	54					
75-84	153	10,402	2	28.6	16	0.9	38	1	14.3	12	0.9	216					
85 and older	33	1,919	0	0.0	0	0.0	0	1	100.0	12	0.1	5					
<b>Other Eligibles</b>	5,949	318,495	110	46.8	1,073	0.7	80	109	46.4	1,070	0.8	41					
64 or younger	1,019	64,858	15	46.9	158	0.6	85	12	37.5	123	0.7	47					
65-74	1,428	78,623	22	46.8	238	0.8	106	24	51.1	265	0.9	44					
75-84	2,199	119,552	48	57.8	452	0.7	83	44	53.0	423	0.8	43					
85 and older	1,303	55,462	25	34.2	225	0.6	46	29	39.7	259	0.6	30					
<b>Unknown</b>	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a,b,c,d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	ANTICONVULSANT						ULCER DRUGS						ANTIDIABETIC						
	Users as %			Users as %			Users as %			Users as %			Users as %			Users as %			
	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Mean No. of Rx	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Mean No. of Rx	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Mean No. of Rx	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>1,105</b>	<b>50.0 %</b>	<b>12,409</b>	<b>0.9</b>	<b>\$55</b>	<b>1,067</b>	<b>48.3 %</b>	<b>11,429</b>	<b>0.7</b>	<b>\$49</b>	<b>791</b>	<b>35.8 %</b>	<b>8,614</b>	<b>0.9</b>	<b>\$36</b>				
<b>Female</b>	622	47.4	6,990	0.9	57	657	50.1	7,109	0.7	50	495	37.7	5,437	0.9	35				
<b>Disabled</b>	491	60.3	5,642	0.9	59	428	52.6	4,754	0.7	48	359	44.1	4,007	0.9	37				
64 or younger	427	61.8	4,880	0.9	61	359	52.0	3,986	0.7	50	289	41.8	3,187	0.9	37				
65-74	54	58.1	646	0.9	44	57	61.3	633	0.7	40	50	53.8	582	0.8	38				
75-84	8	32.0	96	0.8	56	10	40.0	120	0.5	35	19	76.0	228	0.8	33				
85 and older	2	40.0	20	1.1	66	2	40.0	15	0.7	92	1	20.0	10	0.1	4				
<b>Other Eligibles</b>	131	26.3	1,348	0.9	46	229	46.0	2,355	0.8	55	136	27.3	1,430	0.9	31				
64 or younger	25	59.5	251	0.9	71	23	54.8	256	0.8	51	23	54.8	230	1.0	37				
65-74	37	46.3	392	1.0	41	36	45.0	362	0.8	61	27	33.7	282	0.8	36				
75-84	40	22.5	412	0.9	50	83	46.6	836	0.8	53	37	20.8	386	0.9	27				
85 and older	29	14.6	293	0.7	28	87	43.9	901	0.8	55	49	24.7	532	0.8	28				
<b>Male</b>	483	53.7	5,419	1.0	54	410	45.6	4,320	0.7	46	296	32.9	3,177	0.9	37				
<b>Disabled</b>	407	61.3	4,603	1.0	56	325	48.9	3,489	0.7	46	220	33.1	2,371	0.9	37				
64 or younger	396	63.8	4,488	1.0	56	305	49.1	3,266	0.7	45	206	33.2	2,241	0.9	36				
65-74	10	28.6	103	1.0	74	12	34.3	135	0.8	60	12	34.3	122	0.9	49				
75-84	1	14.3	12	0.4	23	7	100.0	76	0.6	60	2	28.6	8	0.6	23				
85 and older	0	0.0	0	0.0	0	1	100.0	12	1.0	118	0	0.0	0	0.0	0				
<b>Other Eligibles</b>	76	32.3	816	0.9	40	85	36.2	831	0.7	45	76	32.3	806	0.9	35				
64 or younger	21	65.6	232	1.0	57	15	46.9	156	0.7	53	14	43.8	147	0.9	33				
65-74	23	48.9	261	0.9	37	17	36.2	191	0.7	55	17	36.2	185	0.7	26				
75-84	18	21.7	187	0.8	29	31	37.3	294	0.7	41	28	33.7	289	1.0	42				
85 and older	14	19.2	136	0.7	32	22	30.1	190	0.6	33	17	23.3	185	1.0	36				
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0				

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis.
  - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	ANTIHYPERTENSIVE					ANALGESICS - Narcotic					CALCIUM BLOCKERS				
	Users as %					Users as %					Users as %				
	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx	Residents	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx	Residents	No. of Users	No. of Bene Users	Mean No. of Rx
<b>All</b>	<b>847</b>	<b>9,066</b>	<b>0.8</b>	<b>\$29</b>	<b>0.8</b>	<b>38.3 %</b>	<b>1,084</b>	<b>11,473</b>	<b>0.6</b>	<b>\$19</b>	<b>0.6</b>	<b>432</b>	<b>4,589</b>	<b>0.9</b>	<b>\$45</b>
<b>Female</b>	493	5,266	0.8	28	0.8	37.6	706	7,597	0.6	19	0.6	273	2,916	0.9	45
<b>Disabled</b>	294	3,265	0.8	28	0.8	36.1	467	5,191	0.6	18	0.6	168	1,830	0.9	47
64 or younger	241	2,652	0.8	29	0.8	34.9	413	4,583	0.6	18	0.6	134	1,445	0.9	46
65-74	40	457	0.9	25	0.9	43.0	44	506	0.6	26	0.6	26	298	1.0	52
75-84	13	156	0.8	28	0.8	52.0	7	84	0.4	5	0.4	6	72	0.8	32
85 and older	0	0	0.0	0	0.0	0.0	3	18	0.4	5	0.4	2	15	0.7	45
<b>Other Eligibles</b>	199	2,001	0.8	28	0.8	40.0	239	2,406	0.6	20	0.6	105	1,086	1.0	43
64 or younger	15	143	0.9	30	0.9	35.7	29	284	0.8	33	0.8	8	81	1.0	50
65-74	23	251	0.9	31	0.9	28.8	53	551	0.6	19	0.6	19	215	1.0	48
75-84	79	812	0.8	27	0.8	44.4	91	947	0.5	19	0.5	36	380	0.9	40
85 and older	82	795	0.8	28	0.8	41.4	66	624	0.6	17	0.6	42	410	1.0	42
<b>Male</b>	354	3,800	0.8	31	0.8	39.4	378	3,876	0.5	19	0.5	159	1,673	0.9	45
<b>Disabled</b>	259	2,846	0.8	31	0.8	39.0	297	3,062	0.5	19	0.5	110	1,179	0.9	48
64 or younger	236	2,581	0.8	31	0.8	38.0	285	2,926	0.5	20	0.5	98	1,064	0.9	48
65-74	19	217	0.8	30	0.8	54.3	9	108	0.6	6	0.6	10	99	0.8	47
75-84	4	48	0.8	8	0.8	57.1	2	16	0.1	1	0.1	2	16	1.0	72
85 and older	0	0	0.0	0	0.0	0.0	1	12	1.3	21	1.3	0	0	0.0	0
<b>Other Eligibles</b>	95	954	0.9	31	0.9	40.4	81	814	0.6	16	0.6	49	494	1.0	38
64 or younger	15	171	0.9	45	0.9	46.9	11	108	0.6	51	0.6	6	72	0.8	41
65-74	21	205	0.9	30	0.9	44.7	14	157	0.8	7	0.8	9	99	0.9	32
75-84	39	407	0.8	28	0.8	47.0	31	314	0.6	14	0.6	19	202	0.9	38
85 and older	20	171	0.9	26	0.9	27.4	25	235	0.4	9	0.4	15	121	1.2	41
<b>Unknown</b>	0	0	0.0	0	0.0	0.0	0	0	0.0	0	0.0	0	0	0.0	0

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis.
  - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	ANALGESICS - ANTI-INFLAMMATORY					DERMATOLOGICAL						
	Users as %		Users as %		Mean Rx \$	Users as %		Users as %		Mean Rx \$		
	No. of Users	%	No. of Users	%		No. of Users	%	No. of Users	%			
<b>All</b>	<b>547</b>	<b>24.7 %</b>	<b>5,995</b>	<b>0.5</b>	<b>\$33</b>	<b>1,640</b>	<b>74.2 %</b>	<b>18,338</b>	<b>0.2</b>	<b>\$9</b>	<b>2,211</b>	<b>23,017</b>
<b>Female</b>	355	27.1	3,925	0.5	32	972	74.1	10,957	0.2	8	1,312	13,786
<b>Disabled</b>	236	29.0	2,691	0.5	31	690	84.8	7,896	0.2	8	814	8,885
64 or younger	204	29.5	2,316	0.5	30	624	90.3	7,109	0.2	8	691	7,508
65-74	28	30.1	336	0.7	35	51	54.8	607	0.2	5	93	1,039
75-84	3	12.0	36	0.7	44	15	60.0	180	0.3	9	25	289
85 and older	1	20.0	3	0.3	15	0	0.0	0	0.0	0	5	49
<b>Other Eligibles</b>	119	23.9	1,234	0.5	34	282	56.6	3,061	0.2	9	498	4,901
64 or younger	17	40.5	179	0.5	23	36	85.7	412	0.2	7	42	408
65-74	21	26.3	220	0.6	34	38	47.5	412	0.2	11	80	808
75-84	38	21.3	410	0.6	30	94	52.8	1,024	0.2	5	178	1,758
85 and older	43	21.7	425	0.5	41	114	57.6	1,213	0.2	11	198	1,927
<b>Male</b>	192	21.4	2,070	0.6	34	668	74.3	7,381	0.3	10	899	9,231
<b>Disabled</b>	141	21.2	1,546	0.6	33	527	79.4	5,918	0.3	10	664	6,967
64 or younger	136	21.9	1,486	0.6	33	506	81.5	5,692	0.3	11	621	6,493
65-74	3	8.6	36	0.6	36	18	51.4	190	0.2	6	35	386
75-84	2	28.6	24	0.5	25	1	14.3	12	0.1	5	7	76
85 and older	0	0.0	0	0.0	0	2	200.0	24	0.2	8	1	12
<b>Other Eligibles</b>	51	21.7	524	0.5	36	141	60.0	1,463	0.2	7	235	2,264
64 or younger	4	12.5	48	0.6	36	24	75.0	249	0.2	6	32	328
65-74	14	29.8	152	0.3	34	28	59.6	322	0.2	5	47	473
75-84	17	20.5	158	0.7	49	41	49.4	424	0.2	8	83	802
85 and older	16	21.9	166	0.5	27	48	65.8	468	0.3	8	73	661
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 1,199 beneficiaries who were in nursing facilities for part of their enrollment and their 11,799 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11  
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS  
 BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 GEORGIA, 2001

Beneficiary Characteristics	No. of Benes with at Least One Part D Excl Rx	% Benes with at Least One Part D Excl Rx	No. of Part D Excl Rx per Bene	Total No. Part D Excl Rx	Total Part D Excl Rx \$	\$ per Part D Excl Rx	Part D Excl Rx \$ as % of All Rx \$	Total No. of Benes
<b>Age</b>								
5 and younger	144,456	36.5	0.7	293,137	5,756,368	20	11.1	395,681
6-14	68,104	20.1	0.4	127,814	3,856,286	30	6.4	339,231
15-20	33,422	21.9	0.4	64,852	1,780,052	27	6.1	152,949
21-44	54,634	21.2	0.5	134,069	3,853,991	29	3.6	257,662
45-64	23,011	38.4	2.0	120,041	2,730,068	23	2.5	59,959
65-74	1,540	35.7	2.0	8,414	158,890	19	2.4	4,313
75-84	705	34.8	2.0	4,122	71,782	17	2.7	2,023
85 and older	355	32.9	1.8	1,981	32,326	16	2.9	1,080
Unknown	0	0.0	0.0	0	0	0	0.0	18
<b>Basis of Eligibility<sup>c</sup></b>								
Aged	1,606	33.5	1.8	8,777	171,228	20	2.8	4,792
Disabled	49,612	36.6	1.6	222,422	7,567,807	34	3.6	135,436
Adults	55,757	21.3	0.4	106,454	1,901,832	18	3.8	262,261
Children	219,151	27.1	0.5	416,561	8,594,860	21	8.8	810,036
Unknown	101	25.8	0.6	216	4,036	19	3.0	391
<b>Gender</b>								
Female	194,527	26.9	0.6	456,231	10,728,928	24	4.8	723,466
Male	131,700	26.9	0.6	298,199	7,510,835	25	5.2	489,448
Unknown	0	0.0	0.0	0	0	0	0.0	2
<b>Race</b>								
White	145,417	31.3	0.8	350,738	8,619,474	25	5.0	464,120
African American	155,710	24.0	0.5	330,469	7,555,624	23	5.0	649,767
Other/unknown	25,100	25.3	0.7	73,223	2,064,665	28	4.5	99,029
<b>Use of Nursing Facilities<sup>d</sup></b>								
Entire year	1,361	61.6	5.4	11,907	211,809	18	3.1	2,211
Part year	833	69.5	4.1	4,892	103,865	21	3.0	1,199
None	324,033	26.8	0.6	737,631	17,924,089	24	5.0	1,209,506
<b>Maintenance Assistance Status</b>								
Cash	125,506	27.5	0.8	365,427	9,811,766	27	3.9	455,893
Medically needy	923	39.9	1.6	3,627	300,820	83	9.7	2,316
Poverty related	133,338	25.6	0.5	247,389	4,732,917	19	8.2	519,853
Other/unknown	66,460	28.3	0.6	137,987	3,394,260	25	6.5	234,854

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001.
- b. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12  
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS PER BENEFIT MONTH  
 BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 GEORGIA, 2001

Beneficiary Characteristics	No. Rx per Bene Mo.	Rx \$ per Bene Mo.	\$ per Rx	Barbiturate \$ per Bene Mo.	Benzodiazepine \$ per Bene Mo.	No. of Bene Mos
All	0.1	\$2	\$24	\$0	\$0	9,894,227
<b>Age</b>						
5 and younger	0.1	2	20	0	0	3,099,662
6-14	0.0	1	30	0	0	2,920,795
15-20	0.1	1	27	0	0	1,233,203
21-44	0.1	2	29	0	0	1,990,306
45-64	0.2	5	23	0	1	575,152
65-74	0.2	3	19	0	1	45,654
75-84	0.2	4	17	0	1	20,339
85 and older	0.2	4	16	0	1	9,064
Unknown	0.0	0	0	0	0	52
<b>Basis of Eligibility<sup>c</sup></b>						
Aged	0.2	4	20	0	1	45,717
Disabled	0.2	5	34	0	1	1,436,739
Adults	0.1	1	18	0	0	1,901,970
Children	0.1	1	21	0	0	6,508,241
Unknown	0.1	3	19	0	1	1,560
<b>Gender</b>						
Female	0.1	2	24	0	0	5,858,946
Male	0.1	2	25	0	0	4,035,273
Unknown	0.0	0	0	0	0	8
<b>Race</b>						
White	0.1	2	25	0	0	3,602,868
African American	0.1	1	23	0	0	5,575,079
Other/unknown	0.1	3	28	0	0	716,280
<b>Use of Nursing Facilities<sup>d</sup></b>						
Entire year	0.5	9	18	1	2	23,017
Part year	0.4	9	21	0	2	11,799
None	0.1	2	24	0	0	9,859,411
<b>Maintenance Assistance Status</b>						
Cash	0.1	2	27	0	0	4,050,760
Medically needy	0.3	23	83	0	2	13,156
Poverty related	0.1	1	19	0	0	3,899,473
Other/unknown	0.1	2	25	0	0	1,930,838

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001.
- b. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.13  
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG NONDUALS<sup>a,b,c</sup>  
 GEORGIA, 2001

Drug Category	No. Users	Rx \$ per User	Total Rx \$	Rx \$ as % of All Part D Excl Rx \$	Total No. Rx.	\$ per Rx	No. Rx as % of All Part D Excl Rx
<b>All</b>	<b>358,327</b>	<b>\$51</b>	<b>\$18,239,763</b>	<b>100.0 %</b>	<b>754,430</b>	<b>\$24</b>	<b>100.0 %</b>
Anorexia or weight loss/gain	2,395	84	200,687	1.1	3,513	57	0.5
Fertility drugs	32	170	5,425	0.0	50	109	0.0
Drugs for cosmetic purposes	798	525	418,687	2.3	3,049	137	0.4
Cough and cold medications	217,195	39	8,430,330	46.2	390,167	22	51.7
Vitamins and minerals	16,866	85	1,441,385	7.9	68,763	21	9.1
Non-prescription drugs	77,418	42	3,285,974	18.0	148,234	22	19.6
Barbiturates	3,564	36	129,574	0.7	24,574	5	3.3
Benzodiazepines	28,266	71	2,005,033	11.0	89,726	22	11.9
Other Part D Excl Rx Drugs	11,793	197	2,322,668	12.7	26,354	88	3.5

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all non-dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2001. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility, those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup>  
NONDUAL BENEFICIARIES, GEORGIA, 2001

Beneficiary Characteristics	No. of Beneficiaries					No. of Beneficiaries						
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown	
<b>All</b>	<b>1,225,089</b>	<b>4,815</b>	<b>135,594</b>	<b>268,497</b>	<b>815,792</b>	<b>391</b>	<b>10,126,084</b>	<b>45,763</b>	<b>1,437,701</b>	<b>1,910,195</b>	<b>6,730,863</b>	<b>1,562</b>
<b>Age</b>												
5 and younger	398,667	2	8,833	81	389,751	0	3,203,253	18	90,611	626	3,111,998	0
6-14	341,455	1	20,642	303	320,509	0	3,015,683	9	229,434	1,950	2,784,290	0
15-20	154,638	0	13,295	40,029	101,294	20	1,258,744	0	145,730	296,342	816,569	103
21-44	262,727	0	41,634	216,812	4,115	166	1,997,108	0	441,780	1,537,328	17,298	702
45-64	60,120	395	48,396	11,118	6	205	576,022	3,318	498,654	73,261	32	757
65-74	4,339	1,858	2,400	81	0	0	45,760	18,187	27,240	333	0	0
75-84	2,039	1,660	350	27	2	0	20,383	16,399	3,884	85	15	0
85 and older	1,084	898	44	45	97	0	9,067	7,831	368	269	599	0
Unknown	20	1	0	1	18	0	64	1	0	1	62	0
<b>Gender</b>												
Female	732,575	3,089	71,405	254,344	403,346	391	5,977,118	29,459	768,451	1,832,690	3,344,956	1,562
Male	492,512	1,726	64,189	14,153	412,444	0	4,148,958	16,304	669,250	77,505	3,385,899	0
Unknown	2	0	0	0	2	8	0	0	0	0	8	0
<b>Race</b>												
White	471,495	1,766	45,721	115,376	308,391	241	3,698,792	15,663	477,467	759,213	2,445,463	986
African American	652,569	1,237	61,415	145,737	444,046	134	5,667,038	11,172	663,315	1,107,180	3,884,836	535
Other/unknown	101,025	1,812	28,458	7,384	63,355	16	760,254	18,928	296,919	43,802	400,564	41
<b>Use of Nursing Facilities<sup>c</sup></b>												
Entire year	2,212	730	1,479	3	0	0	23,021	7,150	15,853	18	0	0
Part year	1,199	353	839	5	2	0	11,811	3,072	8,686	36	17	0
None	1,221,678	3,732	133,276	268,489	815,790	391	10,091,252	35,541	1,413,162	1,910,141	6,730,846	1,562
<b>Maintenance Assistance Status</b>												
Cash	455,893	2,397	120,579	113,400	219,517	0	4,050,774	26,030	1,317,597	803,901	1,903,246	0
Medically needy	2,510	475	2,007	1	27	0	14,103	3,567	10,493	1	42	0
Poverty related	525,428	43	44	73,934	451,016	391	4,121,538	397	340	515,113	3,604,126	1,562
Other/unknown	241,258	1,900	12,964	81,162	145,232	0	1,939,669	15,769	109,271	591,180	1,223,449	0
<b>Managed Care Status</b>												
FFS all year	1,212,916	4,792	135,436	262,261	810,036	391	10,083,506	45,735	1,437,440	1,903,272	6,695,497	1,562
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	12,173	23	158	6,236	5,756	0	42,578	28	261	6,923	35,366	0

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2  
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup>  
 NONDUAL BENEFICIARIES, GEORGIA, 2001

	Bene Mos in Cell J of Table 1		Bene Mos and		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
<b>All</b>	<b>1,225,089</b>	<b>10,126,084</b>	<b>1,212,916</b>	<b>9,894,227</b>	<b>0</b>	<b>231,857</b>		
FFS all year	1,212,916	10,083,506	1,212,916	9,894,227	0	189,279		
FFS part year, with Rx claims	0	0	0	0	0	0		
FFS part year, with no Rx claims	0	0	0	0	0	0		
MC all year, with Rx claims	0	0	0	0	0	0		
MC all year, with no Rx claims	0	0	0	0	0	0		
Unknown	12,173	42,578	0	0	0	42,578		

Source: Data for this table are from the MAX 2001 file for Georgia, released by CMS in 08/2005. This table was produced on 09/19/2006.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.